NCT07237451Recruiting
Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients
Source: ClinicalTrials.gov · Last updated 19 Nov 2025
Brief summary (registry, in English)
The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 13 Nov 2025
- Start date
- 8 Jan 2025
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Grigore T. Popa University of Medicine and Pharmacy
- Diseases
- Chronic kidney disease, Heart failure
- NCT number
- NCT07237451
What you commit to
- Study type: Observational
- Planned participants: 200
- From 8 Jan 2025 to the primary completion date, 1 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- coronary artery disease (including those with a history of acute coronary syndrome, angina pectoris, or prior coronary angiography or CT angiography demonstrating significant coronary artery lesions);
Other illness
- presence of congenital heart disease, decompensated cirrhosis, pregnancy and active malignancies;
- cardiac medical devices, namely metallic joint prostheses, cardiac stent or pacemakers;
- active systemic infections (due to interference with biomarkers that can give false rise values).
Lab values
- eGFR\< 15 mL/min/1.73m2 or patients undergoing dialysis;
Who the study is looking for
- age\>18 years;
- ejection fraction \> 40;
- patients with CKD stage 3-4 (eGFR between 15-60 mL/min/1.73m2), with iSGLT2 recommendation, diabetic and non-diabetic;
- age, sex and CKD stage 3 and 4 matched patients without iSGLT2 administration.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dr. C.I. Parhon Hospital in Iasi Coordinator of this site? Confirm its status | Iași | Romania | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.